提供支持According to 36Kr.com, an artificial heart research and development company Shenzhen CoreHeart Medical Technology Co., Ltd. ("CoreHeart Medical") has received tens of millions of yuan (US$1.4 million) in an angel round of financing, led by Tuspark Ventures Co., Ltd. ("Tuspark Ventures"). Proceeds of this financing will mainly be used for GMP workshop construction, the research and development of maglev heart, the production and animal experiments, with a view to pushing the product into the clinical application as soon as possible.
Founded in 2016, CoreHeart Medical focuses on the research and development of artificial heart and ventricular assist medical products. The company has completed the design finalization of CorHeart 6, the first-generation product of its core product, the subminiature maglev heart, and has begun to register and apply for registration. Currently, the pre-clinical animal experiments are undergoing, and several non-public animal experiments have been completed. The company has got many successful data of more than 100 days from those experiments.
At present, CoreHeart Medical has built a production workshop of more than 8 million square meters in line with the GMP standard and established engineering and biomedical laboratories. In addition, CoreHeart Medical is expanding the medical product pipeline in the cardiovascular field and plans to provide products and equipment for the diagnosis, treatment, monitoring and mechanical assistance of heart surgery for heart disease patients.
CoreHeart Medical has developed the subminiature maglev heart, which has a better structure of the main flow field and the secondary flow field, better magnetic levitation motor design, and control technology, as well as the non-contact bearing technology. Based on these, the product can reduce blood residence time and circulation time, reduce the risk of blood damage, improve the compatibility, and lower cost, to effectively ease the burden on patients.
Founded in 2001, Tuspark Ventures focuses on investing in science and technology innovation-oriented enterprises, mainly in early-stage or growth with great competitiveness. It is committed to the transformation of scientific and technological achievements from Tsinghua University, covering the fields of information technology, life science, and clean technology.
Currently, Tuspark Ventures manages a number of RMB funds including the angel investment fund, with AUM of more than 3 billion yuan.
渝公网安备 50011202502165号
